Sacubitril + valsartan + dapagliflozin
- 1 lab in 1 country
- Funder: Ministero dell’Istruzione, dell’Università e della Ricerca
- 2 of 2 findings with company ties
- Animals1
Outcomes
2Cellular senescence
downin rats1
1 study
Cellular senescence
downin rats1
Sacubitril + valsartan + dapagliflozin decreases cellular senescence in rats.
“The benefit of S/V + D was associated with reactivation of the Nrf2/Keap1 and the AMPK/NAMPT/SIRT axes and reduced markers of cellular senescence”
Animalsmodel of dysmetabolic aging heart failureheart45 weeksfemales
Cardiovascular diabetology21 Mar 2026
Diastolic function
upin rats1
1 study
Diastolic function
upin rats1
Sacubitril + valsartan + dapagliflozin improves diastolic function in rats.
“S/V + D combination further improved diastolic function, reduced left ventricular filling pressures, and enhanced chamber compliance.”
Animalsmodel of dysmetabolic aging heart failureheart45 weeksfemales
Cardiovascular diabetology21 Mar 2026
Latest
1 in 12 monthsCardiovascular Diabetology
Benefits of sacubitril/valsartan alone and in combination with dapagliflozin in a preclinical female model of cardiometabolic and age-related cardiac dysfunction
Experiments in ratsDapagliflozin